NCT01191697View on ClinicalTrials.gov

CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

February 28, 2011

Primary Completion Date

December 31, 2021

Study Completion Date

July 31, 2025

Conditions
Esophageal CancerGastric Cancer
Interventions
DRUG

bevacizumab

Given intravenously on day 1 of each cycle beginning cycle 2

DRUG

trastuzumab

Given intravenously on day 1 of each treatment cycle

DRUG

oxaliplatin

Given intravenously on day one of each cycle beginning cycle 2

DRUG

capecitabine

Taken orally on days 1-14 of each cycle beginning cycle 2

Trial Locations (2)

02114

Massachusetts General Hospital, Boston

02115

Dana-Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Brigham and Women's Hospital

OTHER

collaborator

Massachusetts General Hospital

OTHER

collaborator

Genentech, Inc.

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER